This study determined that CCR4, TMCO1, and SPACA4 may be potential antigens for HNSCC mRNA tumor vaccine development, and patients with immune subtype C3 might benefit most from mRNA vaccination. This evidence concerns the gene CCR4 and head and neck squamous cell carcinoma.